Core Viewpoint - 长江生命科技 has demonstrated significant advancements in cancer immunotherapy, particularly in the development of innovative vaccines targeting specific cancer antigens, which has positively impacted its stock performance [1] Group 1: Stock Performance - Long江生命科技's stock rose nearly 7%, with a current increase of 6.82%, trading at 0.94 HKD, with a transaction volume of 10.43 million HKD [1] Group 2: Research and Development Achievements - The company showcased its research findings at the SITC 2025 conference, focusing on the development of cancer vaccines targeting TROP2, PRAME, and PD-L1, highlighting their potential to inhibit tumor growth [1] - Two innovative vaccines targeting TROP2 protein were disclosed, which is highly expressed in various cancers, including breast cancer, lung cancer, and colorectal cancer [1] - The company also announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with significant T-cell activation effects [1] - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95%, maintaining defensive capabilities even three months post-vaccination, indicating the potential for long-lasting immune memory [1]
港股异动 | 长江生命科技(00775)午后涨近7% 公司在2025 SITC年会展示抑制肿瘤...